Fast, life-saving tests for small labs

Finnish firm Mobidiag has received a EUR 25-million European Investment Bank (EIB) loan to accelerate development and commercialisation of its fast, life-saving tests for small laboratories. The support, provided under the European Fund for Strategic Investments, adds to a previous EUR 15 million EIB loan extended under the InnovFin Infectious Diseases Finance Facility under the EU's Horizon 2020 programme.

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Bosnia and Herzegovina
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czechia
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Georgia

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Bosnia and Herzegovina
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czechia
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Georgia


 

Published: 19 June 2019  
Related theme(s) and subtheme(s)
Health & life sciencesMajor diseases  |  Molecular biology  |  Public health
Industrial research
Innovation
Research policyHorizon 2020
SMEs
Special CollectionsFinancial Instruments - InnovFin
Countries involved in the project described in the article
Finland
Add to PDF "basket"

Fast, life-saving tests for small labs

image

© romaset #189997513, 2019 source: stock.adobe.com

Updated on 19 June 2019

Mobidiag, a molecular diagnostics company, has been developing systems to advance the diagnosis of infectious diseases for laboratories of all sizes since 2008. It is headquartered in Espoo, Finland, and has a subsidiary in Paris.

The firm’s Amplidiag family of tests enables large laboratories to detect gastrointestinal infections and antibiotic resistance.

The new four-year loan is supported by the European Fund for Strategic Investments (EFSI) through the European Growth Finance Facility. It will fund further validation and commercialisation of molecular diagnostics tests on the Amplidiag and Novodiag platforms.

‘Researching and developing ways to stop the spread of infectious diseases is hugely important work but it comes at a high cost,’ says European Commission Vice-President for Jobs, Growth, Investment and Competitiveness Jyrki Katainen. ‘With the support of the EFSI guarantee, the EIB can lend Mobidiag the financing it needs to realise its ambitions and make the world a safer and healthier place to live.’

Mobidiag’s Novodiag range offers automated, on-demand solutions for small laboratories. It is particularly useful in cases where immediate detection of infectious diseases is crucial.

‘Amplidiag is a great success in Nordic countries, where we have closed long-term agreements with large private and public laboratories. We are now moving into France and the UK,’ says Mobidiag CEO Tuomas Tenkanen.

Tenkanen explains that Amplidiag is a platform that can run up to 48 stool samples and provide results after two and a half hours. ‘For Novodiag, the time will be reduced to one hour,’ he adds.

Like Amplidiag, Novodiag tackles antibiotic resistance. It does this by identifying resistance to two widely used types of antibiotics: carbapenem and colistin. Its ease of use minimises risks from human error or fatigue, thereby ensuring accuracy and consistency. ‘A tired laboratory technician at 3 a.m. can run these tests just by following some simple steps that take a few minutes,’ says Tenkanen.

For Tenkanen, InnovFin is valuable in a variety of different ways. ‘Firstly, it fills a gap for companies developing new products as when you get to the commercialisation stage there aren’t many funding sources out there,’ he says. ‘Secondly, the process for obtaining the funding is so thorough that afterwards it becomes much easier to find further financing elsewhere. This has certainly been our experience.’

Project details

  • Project acronym: Mobidiag
  • Participants: Finland (Coordinator)
  • Total costs: € 40 000 000

See also

 

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also
Project website